The study by the Center Valley, Pa.-based implant developer compared Aesculap’s ActivL Artificial Disc with Centinel Spine’s ProDisc-L, reporting outcomes seven years postsurgery — “the longest follow-up of patients from a lumbar arthroplasty [investigational device exemption] trial,” according to Kris Radcliff, MD.
According to the trial, the benefits of both the ActivL and ProDisc-L remained seven years postprocedure, “with significant improvements from baseline observed in pain, function, and opioid use.” However, patients with the ActivL disc showed better range of motion than those with the ProDisc-L, and 57 percent of ProDisc-L patients reported “serious adverse events,” compared with 38 percent of ActivL patients.
Another study from this year published in the Journal of Orthopaedic Surgery and Research on the ActivL found that, three years postsurgery, patients had overall better sagittal alignment and experienced less pain.
Read more about Aesculap’s study here.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
